What it sells
AI cancer research.
Business model breakdown
Buyer: who owns the budget?
UnverifiedBusiness development and R&D leads at pharma and biotech, and investors evaluating combination trials.
Trigger: what makes them buy now?
Resistant cells regrow after standard of care; need to find the one or two effective combinations among 60+ billion; want a sense check before running a combination trial.
Workflow: what inputs become what output?
Model ranks combinations in seconds; partners ask for the right pairing within a portfolio or delivery cargo or a sense check of a trial, with a first free check within hours, then deeper collaboration.
Economics: what it saves and how it charges
Builds internal combination programs and works with pharma/biotech/investors (partnership model); validation claim of 86% accuracy on ASCO 2026 prospective calls.
Distribution: how it reaches customers
Email outreach and public prediction posts on X.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-18 | — | 2,55 Millionen Euro | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.